A.S. Fauci, The syndrome of Kaposi's sarcoma and opportunistic infections: an epidemiologically restricted disorder of immunoregulation, Ann. Int. Med. 96 (1982), p. 777.J.E. Menitove et al., T. lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates, N. Engl. J. Med. 308 (1983), p. 83.M.M. Lederman et al., Impaired cell-mediated immunity in patients with classic hemophilia, N. Engl. J. Med. 308 (1983), p. 79.M.V. Ragni et al., Acquired immunodeficiency-like syndrome in two haemophiliacs, Lancet 1 (1983), p. 213.J.L. Marx, Spread of AIDS sparks new health concern, Science 219 (1983), p. 42.J.L. Marx, Health officials seek ways to halt AIDS, Science 219 (1983), p. 271.

1983 ◽  
Vol 26 (3) ◽  
pp. 329-330
Author(s):  
B HABIBI
Keyword(s):  
T Lymphocyte ◽  
Kaposi's Sarcoma ◽  
Opportunistic Infections ◽  
Kaposi’S Sarcoma ◽  
Lymphocyte Subpopulations ◽  
Health Concern ◽  
Cell Mediated Immunity ◽  
T Lymphocyte Subpopulations ◽  
Acquired Immunodeficiency

Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.

1986 ◽  
Vol 4 (4) ◽  
pp. 544-551 ◽  
Author(s):  
F X Real ◽  
H F Oettgen ◽  
S E Krown
Keyword(s):  
Acquired Immunodeficiency Syndrome ◽  
Kaposi's Sarcoma ◽  
Opportunistic Infections ◽  
Kaposi’S Sarcoma ◽  
Response Duration ◽  
High Dose ◽  
Median Response ◽  
Major Response ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

The efficacy of recombinant leukocyte A interferon (rIFN-alpha A [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome was evaluated in sequential trials using high doses (36 X 10(6) units) and low doses (3 X 10(6) units) of interferon. A major response was seen in 38% of patients treated at the high dose, with a median response duration of 18 months. At the low dose, the major response rate was 3%; dose escalation to 36 X 10(6) units resulted in an additional major response rate of 17% in low-dose nonresponders, with a median response duration of 10 months. Four of 11 patients who achieved a complete response remain free of disease, whereas all partial responders have shown disease progression. Unacceptable toxicity occurred in 27% of patients initially treated at the high dose and only in 10% of those who had progressive dose escalation up to 36 X 10(6) units. Prior opportunistic infections correlated negatively with therapeutic response, whereas large tumor burden and gastrointestinal involvement did not. Responding patients showed a significantly longer survival and a lower incidence of subsequent opportunistic infections than nonresponders. However, from our study we cannot determine whether rIFN-alpha A has an effect on the natural history of Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome.

scholarly journals The immunosuppressive effects of volatile versus intravenous anesthesia combined with epidural analgesia on kidney cancer: a pilot randomized controlled trial

2020 ◽  
Vol 73 (6) ◽  
pp. 525-533
Author(s):  
Sergey Mihailovich Efremov ◽  
Victoria Sergeevna Kozireva ◽  
Gleb Borisovich Moroz ◽  
Marat Nikolaevich Abubakirov ◽  
Olga Sergeevna Shkoda ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Epidural Analgesia ◽  
Kidney Cancer ◽  
T Lymphocyte ◽  
Lymphocyte Subpopulations ◽  
Cell Mediated Immunity ◽  
Inhalational Anesthesia ◽  
Intravenous Anesthesia ◽  
Thoracic Epidural ◽  
T Lymphocyte Subpopulations

Background: The aim of this study was to test the hypothesis that the use of inhalational anesthesia leads to higher suppression of the cell-mediated immunity compared to total intravenous anesthesia in patients undergoing kidney cancer surgery under combined low thoracic epidural analgesia and general anesthesia. Methods: Patients were randomly allocated to either propofol-based (intravenous anesthetic) or sevoflurane-based (volatile anesthetic) anesthesia group with 10 patients in each group, along with epidural analgesia in both groups. Amounts of natural killer cells, total T lymphocytes, and T lymphocyte subpopulations in the blood samples collected from the patients before surgery, at the end of the surgery and postoperative days 1, 3, and 7, were determined by flow cytometric analysis. The natural killer (NK) cell count served as the primary endpoint of the study, whereas the total T lymphocyte count and cell counts for T lymphocyte subpopulations were used as the secondary endpoint. . Results: Our study showed that there were no significant differences in the amount of NK cells, total T lymphocytes, regulatory T cells, and T-helper cells, cytotoxic T lymphocytes, and their subpopulations between the propofol- and sevoflurane-based anesthesia groups when the anesthesia was administered in combination with epidural analgesia. Conclusions: The results of this pilot study did not support the hypothesis that the use of inhalational anesthesia leads to higher suppression of the cell-mediated immunity than that of total intravenous anesthesia in patients undergoing kidney cancer surgery under combined low thoracic epidural analgesia and general anesthesia.

Altered distribution of T-lymphocyte subpopulations in lymph nodes from patients with acquired immunodeficiency-like syndrome and hemphilia

1983 ◽  
Vol 103 (3) ◽  
pp. 407-410 ◽  
Author(s):  
Paul R. Meyer ◽  
Robert L. Modlin ◽  
Darleen Powars ◽  
Nadia Ewing ◽  
John W. Parker ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
T Lymphocyte ◽  
Lymphocyte Subpopulations ◽  
T Lymphocyte Subpopulations ◽  
Acquired Immunodeficiency

Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.

1984 ◽  
Vol 2 (10) ◽  
pp. 1115-1120 ◽  
Author(s):  
L J Laubenstein ◽  
R L Krigel ◽  
C M Odajnyk ◽  
K B Hymes ◽  
A Friedman-Kien ◽  
...  
Keyword(s):  
Immune Deficiency ◽  
Complete Remission ◽  
Partial Remission ◽  
Kaposi's Sarcoma ◽  
Opportunistic Infections ◽  
Kaposi’S Sarcoma ◽  
Response Duration ◽  
Median Response ◽  
Stage Disease

An epidemic of disseminated Kaposi's sarcoma in male homosexuals has recently been described. Forty-one evaluable patients with epidemic Kaposi's sarcoma were treated with etoposide. The majority of these patients had early stage disease, no prior opportunistic infections, and no prior therapy. Twelve patients (30%) achieved complete remission, 19 (46%) partial remission, and ten (24%) no response. With follow-up time to 31 months, the median response duration is nine months. The median survival of patients with complete and partial remissions has not been reached. A combination of doxorubicin (Adriamycin, Adria Laboratories, Columbus, Ohio), bleomycin, and vinblastine (ABV) was used in 31 evaluable patients with epidemic Kaposi's sarcoma. The majority of these patients had late stage disease, prior opportunistic infections, or had failed prior treatment. Seven patients (23%) achieved complete remission, 19 (61%) partial remission, and five (61%) no response. With follow-up time to 24 months, the median response duration is eight months. The projected median survival for all patients treated with ABV is nine months. Both regimens were well tolerated, with an overall response rate of 76% for etoposide and 84% for ABV. However, while successfully treating the Kaposi's sarcoma, the underlying immune deficiency in these patients has persisted. Future treatments of Kaposi's sarcoma will need to focus on reversing the underlying immune incompetence as well as controlling the malignant manifestations of Kaposi's sarcoma arising in relation to the acquired immune deficiency syndrome.

Sign in / Sign up

Export Citation Format

Share Document